The quest to measure biological aging has long been dominated by single-time-point “clocks” that calculate a person’s biological age as a static number. But a growing body of evidence suggests that the speed at which we age, not just the current state, may be far more informative for testing interventions that target the aging process itself. A new biomarker derived from the multi-decade Framingham Heart Study, called the Pace of Aging, is gaining attention as a rate-based measure that can detect the effects of calorie restriction and other geroprotective strategies in relatively short clinical trials.

Why measure the pace of aging?

Traditional biomarkers of aging, such as telomere length or DNA methylation patterns, provide a snapshot of molecular wear and tear at a single moment. They have been widely used in observational studies and commercial tests, but their responsiveness to interventions has been inconsistent. For clinical trials aimed at slowing aging, researchers need an endpoint that changes meaningfully over months or a few years, not decades. The Pace of Aging approach fills that gap by measuring how quickly physiological decline accumulates across multiple organ systems over time.

The concept was introduced by investigators working with the Framingham Heart Study, one of the longest-running epidemiological studies in medical history. Instead of relying on one biological sample, the Pace of Aging uses repeated clinical measurements collected over years to estimate the rate of deterioration in cardiovascular, metabolic, pulmonary, and renal function. The result is a dynamic metric that reflects the cumulative effects of genetics, environment, and lifestyle on the body’s systems.

The Framingham approach to measuring pace

To develop the Pace of Aging biomarker, researchers analyzed data from thousands of Framingham participants who underwent standardized clinical examinations at multiple time points. The measurements include blood pressure, body mass index, cholesterol levels, blood glucose, pulmonary function, and kidney function tests. By applying statistical models that combine these serial measurements, the team generated a single trajectory for each individual, representing how many years of physiological aging occur per chronological year.

A Pace of Aging score of 1 indicates that a person’s biology ages at the same pace as chronological time. A score above 1 means accelerated aging, while a score below 1 indicates slower aging. In a 2024 analysis of approximately 5,000 participants, researchers linked a one-year faster Pace of Aging to significantly higher risks of cardiovascular disease and death, even after adjusting for traditional risk factors. This association provides strong evidence that the pace measure captures meaningful biological information beyond any single biomarker.

Validation in the CALERIE trial

The most compelling demonstration of the Pace of Aging’s utility came from the CALERIE trial, a randomized controlled study funded by the National Institute on Aging. CALERIE tested the effects of a 12% reduction in caloric intake on healthy, non-obese adults over two years. Using blood biomarkers collected at baseline and at 12 months, researchers calculated changes in the Pace of Aging score. The results showed that caloric restriction slowed the pace of aging by 2–3% per year, a modest but statistically significant effect.

This finding is notable because it shows that a rate-based biomarker can detect changes after only one year of an intervention. In contrast, most single-time-point clocks require longer follow-up or larger sample sizes to reveal intervention effects. The CALERIE results also predicted reduced morbidity and mortality in external cohorts, suggesting that a 2–3% slowing of the pace is clinically meaningful. For the first time, a biomarker has demonstrated both sensitivity to an intervention and correspondence with hard outcomes like disease and death.

Rate versus state: a paradigm shift for clinical trials

For decades, drug developers seeking to test anti-aging therapies have faced a fundamental problem: aging itself is not a recognized indication, and clinical trials typically rely on disease-specific endpoints. The FDA and other regulators have shown willingness to consider biomarkers of aging as surrogate endpoints, but only if they are robust and reproducible. The Pace of Aging offers a way forward by turning aging into a measurable process rather than a distant outcome.

Because the pace metric integrates multiple organ systems, it is less likely to be swayed by acute stress or transient fluctuations that affect epigenetic clocks. DNA methylation clocks, for example, can respond to short-term inflammation or medication, making them noisy in trial settings. The Pace of Aging, by contrast, reflects a longer-term trajectory, which may make it more reliable for assessing interventions that aim to slow the underlying biology of aging.

An additional advantage is the ability to use the Pace of Aging in adaptive trial designs. Researchers can monitor changes in the pace score after a few months and decide whether to continue, discontinue, or modify the intervention. This approach could reduce the cost and duration of phase 2 trials for geroprotectors, which have historically been hampered by the need for large cohorts and long follow-up periods.

Challenges to implementation

Despite its promise, the Pace of Aging is not without limitations. The method requires repeated clinical measurements over time, which is more complex and expensive than a simple blood draw. In real-world settings, missing data and inconsistent measurement protocols can undermine the accuracy of the trajectory. Researchers have called for harmonizing real-world data and repeated samplings to improve the reliability of rate-based biological age measures across cohorts.

Another challenge is the need for standardized algorithms and reference populations. The Framingham-derived model was built on a primarily Caucasian cohort, and it is unclear how well it translates to other ethnic and socioeconomic groups. Open-access algorithms and cross-cohort validation are essential before the Pace of Aging can be widely adopted in clinical practice or regulatory evaluations.

Commercial hype and unproven claims

Industry interest in the Pace of Aging has spiked after the commercial launch of direct-to-consumer tests that claim to measure biological pace. These products often use a single blood sample or a handful of measurements, which is fundamentally incompatible with the longitudinal design required to estimate a rate. Experts have cautioned that such tests are not clinically validated and may mislead consumers who are seeking actionable insights about their health.

The gap between rigorous research and consumer access is not unique to the Pace of Aging. Similar issues have arisen with telomere length tests and epigenetic clocks, which were marketed to consumers long before they were clinically proven. The Pace of Aging is a valuable tool for research, but its translation to consumer products must be guided by evidence and regulatory oversight, not hype.

Toward harmonization and clinical use

Moving forward, the success of the Pace of Aging will depend on collaboration among research groups to share algorithms and data. Several international consortia are already working on harmonizing biological age measures, and the Pace of Aging could become a model for how to integrate longitudinal data from electronic health records, clinical trials, and wearable devices. If these efforts succeed, rate-based biomarkers could become standard endpoints in longevity medicine and drug development.

There is also potential for combining the Pace of Aging with molecular biomarkers such as methylomic or proteomic signatures. While the pace measure captures metabolic and organ function, molecular clocks provide insight into cellular machinery. A composite index that integrates both rate and state could offer a more holistic picture of aging, and might be even more predictive than either alone.

The next few years will be critical. As more clinical trials adopt the Pace of Aging as an exploratory endpoint, we will learn whether it truly delivers on its promise. The ultimate test will be whether a drug that slows the pace also reduces the incidence of age-related diseases and extends healthspan. If that evidence emerges, the pace of aging could become one of the most important biomarkers in preventive medicine.

Yet the idea that aging can be measured as a speed is not entirely new. In the 1990s, researchers proposed using longitudinal decline in physical and cognitive function to estimate “frailty” trajectories. These earlier concepts laid the groundwork for the Framingham score, but they were hindered by data scarcity and analytical limitations. The current interest in rate-based biomarkers reflects a broader shift in the aging field away from discrete biological age estimates and toward dynamic, process-oriented measures.

The direct-to-consumer longevity testing market has also seen a pattern of boom-and-bust cycles. Telomere testing gained popularity in the 2000s, only to be abandoned after replication studies failed to support its predictive power. DNA methylation clocks took its place in the 2010s, and are now widely used by startups and wellness clinics. The Pace of Aging is entering a crowded field, but its longitudinal design may offer a competitive edge if it can overcome the logistical hurdles that have limited previous rate-based approaches.

As with any new biomarker, the key will be rigorous validation. The history of aging biomarkers teaches us that no measure is perfect, and those that promise a simple answer to a complex question are often overhyped. The Pace of Aging is a welcome addition to the toolkit, but it should be seen as a complement to, not a replacement for, existing methods. By combining the best of longitudinal and molecular approaches, researchers may finally have the tools to test and deliver the first truly effective anti-aging therapies.

The PEARL Trial and Recent Advances in Human Rapamycin Research

In October 2023, the PEARL trial, a clinical study investigating low-dose rapamycin for age-related decline, reported preliminary data showing improved immune function in older adults, advancing safety assessments for anti-aging applications. This development marks a critical transition from animal models to targeted human trials, as highlighted by updates on fightaging.org, which note increased human trials and a shift towards evidence-based protocols in longevity research. The trial focuses on mTOR pathway inhibition to mimic calorie restriction and enhance autophagy, addressing optimal dosing windows suggested in a 2023 review published in the journal ‘Aging Cell’. Researchers emphasize the need for precise dosing to maximize anti-aging effects while minimizing potential side effects, such as immunosuppression, which has been a concern in earlier uses of rapamycin as an immunosuppressant for transplant patients. The preliminary data from the PEARL trial provides a foundation for larger-scale studies, aiming to establish standardized protocols that could pave the way for FDA-approved anti-aging therapies. As fightaging.org reports, this trend reflects a broader movement in longevity research towards personalized medicine and combination therapies, with biomarkers like mTOR inhibition being prioritized for monitoring efficacy. The ongoing trials are not only refining safety profiles but also exploring how low-dose rapamycin can be integrated into holistic aging interventions, potentially reducing the reliance on off-label prescriptions that lack regulatory oversight. This shift is driven by growing consumer interest in longevity solutions, yet it raises ethical questions about accessibility and evidence-based adoption in aging populations.

Autophagy Enhancement and the Science Behind Rapamycin’s Anti-Aging Mechanisms

Recent studies underscore rapamycin’s role in autophagy enhancement, a cellular process crucial for clearing damaged components and promoting longevity. The 2023 review in ‘Aging Cell’ suggests optimal dosing windows for anti-aging effects, indicating that intermittent or low-dose regimens may balance benefits with risks, such as metabolic disruptions observed in higher doses. This scientific insight builds on decades of research, starting with animal studies in the early 2000s that demonstrated rapamycin’s lifespan extension in mice by inhibiting the mTOR pathway, a key regulator of growth and metabolism. Fightaging.org has covered these updates, noting that the focus on autophagy aligns with broader trends in longevity research, where enhancing cellular repair mechanisms is seen as a promising strategy against age-related diseases. The review emphasizes that while rapamycin shows promise, its application requires careful calibration to avoid adverse effects, a challenge that ongoing clinical trials aim to address. For instance, the PEARL trial’s preliminary data on immune function improvements in older adults highlights the potential for rapamycin to bolster resilience against infections, a common concern in aging. However, experts caution that without robust human data, off-label use remains speculative, leading to ethical dilemmas in clinical practice. The longevity research trend, as reported in recent analyses, advocates for standardized dosing in clinical settings, using biomarkers to track mTOR inhibition and autophagy activation. This approach could transform rapamycin from a repurposed drug into a targeted anti-aging intervention, but it necessitates rigorous validation through trials like PEARL. As such, the scientific community is calling for more collaborative efforts to pool data and establish consensus on dosing guidelines, ensuring that future applications are grounded in evidence rather than anecdotal claims.

Ethical and Regulatory Challenges in the Off-Label Use of Rapamycin for Anti-Aging

The off-label prescription of rapamycin for anti-aging poses significant ethical and regulatory challenges, as it lacks FDA approval for this indication, raising concerns about patient safety and informed consent. In the United States, rapamycin is approved by the FDA as an immunosuppressant for preventing organ transplant rejection, but its use for longevity purposes falls outside regulated frameworks, leading to potential misuse and unequal access. The ongoing clinical trials, such as the PEARL trial, aim to generate evidence that could reshape longevity markets and influence healthcare policies, moving towards evidence-based adoption in aging populations. Fightaging.org has reported on this shift, highlighting how increased human trials are addressing the gap between animal studies and real-world applications, but controversies persist regarding the commercialization of unproven therapies. For example, some clinics offer rapamycin off-label without adequate monitoring, exploiting consumer demand for anti-aging solutions, which underscores the need for stricter regulatory oversight. The ethical debates center on whether off-label use should be permitted in the absence of comprehensive safety data, with proponents arguing for patient autonomy and opponents warning of unknown long-term risks. Recent reports advocate for standardized dosing in clinical settings, as seen in the longevity research trend focusing on biomarkers like mTOR inhibition, to mitigate these issues. However, regulatory bodies like the FDA have been cautious, requiring robust clinical evidence before approving new indications, a process that the PEARL trial and similar studies are advancing. This tension between innovation and regulation highlights the broader challenges in the longevity industry, where rapid scientific progress often outpaces policy development. As such, analysts predict that successful trials could prompt regulatory reviews, potentially leading to approved anti-aging uses, but this hinges on transparent data sharing and ethical trial conduct. The impact on healthcare policies could include updated guidelines for geriatric care, integrating rapamycin into preventative aging strategies if proven safe and effective, thereby reducing the burden of age-related diseases on healthcare systems.

The interest in rapamycin for anti-aging applications has evolved from early animal studies in the 2000s, where research demonstrated its lifespan-extending effects in model organisms like mice, to current human trials focusing on safety and dosing. Prior to this, rapamycin was primarily used in transplant medicine after FDA approval in the 1990s, setting a precedent for its immunosuppressive properties. Comparing it to older or similar treatments, such as metformin—another calorie restriction mimetic—rapamycin offers a distinct mechanism through mTOR inhibition, but both share challenges in balancing efficacy with side effects. For instance, metformin has a longer history of use for diabetes and is being studied for anti-aging, yet rapamycin’s more potent autophagy enhancement may provide unique advantages, as suggested by the 2023 ‘Aging Cell’ review. Controversies in the field include debates over optimal dosing strategies and the risk of infections, which earlier transplant studies have addressed through careful monitoring, highlighting recurring patterns in drug repurposing. The evolution of longevity research shows a shift from anecdotal evidence to rigorous clinical protocols, with fightaging.org documenting this transition and advocating for evidence-based approaches to avoid the pitfalls of past trends, such as the unregulated use of supplements like resveratrol.

Regulatory actions in the same field have been incremental, with the FDA historically cautious about approving anti-aging drugs due to the complexity of aging as a condition. Previous approvals, like those for rapamycin in transplant rejection, relied on clear biomarkers and clinical endpoints, a framework now being applied to anti-aging trials. The PEARL trial’s focus on immune function as a biomarker mirrors this approach, aiming to establish measurable outcomes for regulatory review. As longevity research trends emphasize personalized medicine, the lessons from older treatments underscore the importance of standardized dosing and long-term safety data, which ongoing rapamycin trials are poised to provide. This context helps readers understand the scientific and regulatory landscape, illustrating how rapamycin’s journey from transplant drug to potential anti-aging therapy reflects broader efforts to validate interventions through clinical evidence, ultimately aiming to improve healthspan in aging populations.